NCT02676843View on ClinicalTrials.gov

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 25, 2018

Study Completion Date

November 25, 2018

Conditions
Frontotemporal Lobar Degeneration (FTLD)Frontotemporal Dementia (FTD)Tauopathies
Interventions
DRUG

18F-AV-1451

A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.

Trial Locations (1)

10032

Morton A. Kreitchman PET Center, New York

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Columbia University

OTHER

NCT02676843 - Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations | Biotech Hunter | Biotech Hunter